Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.

PURPOSE To identify the optimal schedule for infusion of cytarabine (ara-C) given with cladribine (2-CdA) to pediatric patients with acute myeloid leukemia (AML), and to compare the effects of the two schedules on the pharmacokinetics of ara-C triphosphate (ara-CTP) in leukemic cells. PATIENTS AND METHODS Forty-nine pediatric patients with newly diagnosed primary AML received a 5-day course of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d. They were randomly assigned to receive ara-C as either a 2-hour daily infusion (arm A) or a continuous infusion (arm B). Cellular pharmacokinetics were studied on days 1 and 2. All patients then received two courses of remission induction chemotherapy with daunorubicin, ara-C, and etoposide (DAV). RESULTS Thirty-two percent of patients (seven of 22) in arm A and 63% (17 of 27) in arm B entered complete remission (P =.045) after ara-C and 2-CdA therapy. Coadministration of 2-CdA increased the intracellular concentration of ara-CTP in 20 of 36 patients, although we found no statistically significant difference between the treatment arms in this effect (P =.63). The incidence of toxicity did not differ significantly between the two treatment arms (P =.53). After two courses of DAV, the rate of complete remission was 91% in arm A and 96% in arm B (P =.58). CONCLUSION Intracellular accumulation of ara-CTP is increased when 2-CdA is given with ara-C, but no schedule-dependent differences in this effect were seen. The combination of 2-CdA and ara-C seems to be effective therapy for pediatric AML.

[1]  S. Raimondi,et al.  Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Berthold,et al.  Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Niemeyer,et al.  Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 , 2001, Leukemia.

[4]  S. Raimondi,et al.  Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects , 2000, Leukemia.

[5]  G. Henze,et al.  Definition of a standard‐risk group in children with AML , 1999, British journal of haematology.

[6]  J. Buckley,et al.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.

[7]  J. Krischer,et al.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .

[8]  Juliusson,et al.  Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  R. Krance,et al.  Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. , 1994, Blood.

[10]  M. Schell,et al.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Plunkett,et al.  Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. , 1992, Cancer research.

[12]  G. Juliusson,et al.  On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. , 1991, Cancer research.

[13]  M. Schell,et al.  A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Plunkett,et al.  Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. , 1989, Blood.

[15]  E. Estey,et al.  Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Plunkett,et al.  Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. , 1988, Cancer research.

[17]  E. Estey,et al.  Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. , 1987, Leukemia.

[18]  E. Estey,et al.  Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine Therapy , 1987 .

[19]  W. Plunkett,et al.  Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. , 1987, Cancer treatment reports.

[20]  Jan Liliemark,et al.  Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine , 1985 .

[21]  W. Plunkett,et al.  Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. , 1980, Cancer research.

[22]  R. Momparler,et al.  Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. , 1968, The Journal of biological chemistry.

[23]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.

[24]  G. Reaman,et al.  Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  E. Estey,et al.  Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.

[26]  M. Ratain,et al.  Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Estey,et al.  Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.

[28]  E. Estey,et al.  Biochemical modulation of arabinosylcytosine for therapy of leukemias. , 1993, Leukemia & lymphoma.

[29]  E. Estey,et al.  Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Plunkett,et al.  Separation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate and 9-β-d-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography , 1987 .

[31]  E. Estey,et al.  Pharmacologically directed ara-C therapy for refractory leukemia. , 1985, Seminars in oncology.